Pembrolizumab for Long COVID Syndrome

This trial explores whether pembrolizumab, a drug typically used for certain cancers, can reduce long-term neurological symptoms in people who have recovered from COVID-19. These symptoms might include ongoing issues like headaches, dizziness, or trouble with walking. The trial seeks individuals who had COVID-19 at least six months ago and still experience these persistent neurological problems. Participants will receive one dose of the drug and attend seven clinic visits over seven months. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking research.

The trial does not specify if you need to stop taking your current medications, but it excludes those on oral steroids or other immunosuppressive medications that could affect the study's outcome. It's best to discuss your specific medications with the study team.

Research has shown that pembrolizumab, a drug approved for treating some cancers, is under study for its potential to alleviate long-term neurological symptoms after COVID-19. In past studies with cancer patients, most tolerated pembrolizumab well, with few experiencing serious side effects. Some reported mild to moderate issues like tiredness or nausea.

Pembrolizumab is unique because it targets the immune system differently from current treatments for Long COVID. Most existing treatments focus on managing symptoms, like fatigue and brain fog, or addressing inflammation with steroids. Pembrolizumab, however, is a monoclonal antibody that works by blocking a specific protein called PD-1, which helps activate the immune system to fight lingering effects of the virus. Researchers are excited because this approach could offer a more targeted way to address the underlying immune dysfunction in Long COVID, potentially leading to more effective and longer-lasting relief for patients.

Research suggests that pembrolizumab, a drug approved for treating certain cancers, might help reduce long-term neurological symptoms caused by COVID-19. Although no direct proof exists yet for its use in Long COVID, the drug aids the immune system in addressing ongoing issues. This is important because some Long COVID symptoms may result from continuous immune responses. Early studies in other conditions have shown that pembrolizumab can alter immune system function, which is why researchers are considering it here. In cancer treatment, it has helped stabilize the disease, indicating it might also manage ongoing symptoms. Participants in this trial will receive a single dose of pembrolizumab 200 mg IV to evaluate its potential benefits for Long COVID.¹²³⁵⁶